Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Yahoo FinanceMay 2 22:02

Deciphera Pharmaceuticals Cut to Neutral From Buy by Guggenheim

Deciphera Pharmaceuticals Cut to Neutral From Buy by Guggenheim

Dow JonesMay 1 01:12

Guggenheim Downgrades Deciphera Pharmaceuticals to Neutral

Guggenheim analyst Michael Schmidt downgrades Deciphera Pharmaceuticals from Buy to Neutral.

Analyst UpgradesMay 1 01:03

Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

In the last three months, 5 analysts have published ratings on Deciphera Pharmaceuticals (NASDAQ:DCPH), offering a diverse range of perspectives from bullish to bearish.The table below summarizes thei

BenzingaApr 30 21:01

Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target Is $26

Deciphera Pharmaceuticals (DCPH) has an average outperform rating and a price target range of $23 to $30, according to analysts polled by Capital IQ. Price: 25.17, Change: -0.11, Percent Change: -0.44

MT NewswiresApr 30 19:10

JMP Downgrades Deciphera Pharmaceuticals to Market Perform

Deciphera Pharmaceuticals (DCPH) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $23 to $30. Price: 25.21, Change: -0.07, Percent Ch

MT NewswiresApr 30 19:02